New APA Study Shows a Spike in Anxiety Among a Large Swath of America

By |2023-05-10T14:11:20-07:00May 10th, 2023|Brief Bulletins from the Field, We Know Psychiatry|

According to the American Psychiatric Association's annual poll, 70% of adults in the United States report feeling anxious or extremely anxious about their own and their family's safety. This number is 6% higher than in the past two years, although lower than during the early stages of the pandemic in [...]

Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression

By |2023-02-08T08:34:35-08:00February 8th, 2023|Brief Bulletins from the Field, We Know Psychiatry|

Objective: To compare the efficacy and speed of achieving remission/response in treatment-resistant depression (TRD) patients treated with subanesthetic intravenous (IV) ketamine and intranasal (IN) esketamine approved by the US Food and Drug Administration (FDA). Methods: The study was observational and included 62 adults with TRD who received up to 6 [...]

Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

By |2019-10-24T09:38:15-07:00October 24th, 2019|Brief Bulletins from the Field, We Know Psychiatry|

Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies targeting monoamines. The recent approval of the NMDA (N-methyl-d-aspartate) [...]

FDA Approves Intranasal Ketamine for Major Depressive Disorder

By |2019-03-06T08:05:04-08:00March 6th, 2019|Brief Bulletins from the Field, We Know Psychiatry|

The Food and Drug Administration yesterday approved an intranasal form of esketamine for treatment-resistant depression in adults who have failed at least two oral antidepressants of different classes. The spray, from Janssen Pharmaceutical (Spravato) is available in tamper-resistant prepackaged units of one, two, or three devices to deliver the prescribed doses [...]

Combination of Ketamine and Naltrexone Shows Promise for Addiction Treatments and Depression

By |2019-01-18T11:06:43-08:00January 18th, 2019|Brief Bulletins from the Field, We Know Psychiatry|

  A preliminary study of five patients suffering from both depression and substance abuse disorders suggest that isn’t the case. The study was published Jan. 9 in the journal JAMA Psychiatry. Substance abuse and depression are common in many patients, and efforts to treat both conditions simultaneously have had limited [...]

Powerful Ketamine Nasal Spray Shows Promise in Quickly Treating Depressive Symptoms

By |2018-04-19T09:17:31-07:00April 16th, 2018|We Know Psychiatry|

A more powerful ketamine (esketamine) nasal spray, combined with standard-of-care treatment, shows promise in quickly tamping-down depressive symptoms, according to results of a phase 2 study published April 16 in the American Journal of Psychiatry. In a study of 68 patients randomly assigned to either esketamine or placebo with standard-of-care treatment, [...]

NIMH: Ketamine-Like Hallucinogens May Offer New Hope for Treatment-Resistant Depression

By |2021-11-11T17:04:19-08:00November 16th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

In 2006, psychiatrist Carlos A. Zarate Jr, MD, and colleagues at the National Institute of Mental Health (NIMH) published a seminal finding in Archives of General Psychiatry (now JAMA Psychiatry): A single intravenous dose of ketamine—an anesthetic agent with hallucinogenic properties—produced robust antidepressant effects in patients with treatment-resistant depression (TRD) [...]

Research into Hallucinogens Gives Hope to the Hopeless and Fuels a Drug Epidemic: A Tale of Two Disparate Worlds

By |2021-11-11T17:05:57-08:00October 26th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Alan F. Schatzberg, MD   Madness Rising Research into Hallucinogens Gives Hope to the Hopeless and Fuels a Drug Epidemic: A Tale of Two Disparate Worlds By James M. La Rossa Jr. Editorial Director and Publisher   In Robert Stone’s influential book about the heroin trade that permeated the Vietnam [...]

AFSP: Can Ketamine Rapidly Reduce Suicidal Ideation?

By |2021-11-11T17:07:05-08:00June 22nd, 2017|Brief Bulletins from the Field, We Know Psychiatry|

This work was sponsored by a Young Investigator Grant from the American Foundation for Suicide Prevention (AFSP) BACKGROUND Suicide is preventable, yet still remains a worldwide cause of death in part due to a lack of available medical interventions that can work during a suicidal crisis. Most potentially helpful medications [...]

Title

Go to Top